Table 2.

Clinical outcomes according to time of regorafenib treatment initiation (pre- or post-inclusion of the ReDOS strategy in NCCN Guidelines)

Clinical characteristic	Study population (N = 703)
	Pre-inclusion of ReDOS in NCCN Guidelines (n = 310)	Post-inclusion of ReDOS in NCCN Guidelines (n = 393)
Dose classification at index date, n (% [95% CI])*
Flexible dose (< 84 tablets/28 days†)	66 (21.3 [16.9, 26.3])	178 (45.3 [40.3, 50.4])
Standard dose (≥ 84 tablets/28 days)	244 (78.7 [73.7, 83.1])	215 (54.7 [49.6, 59.7])
Patients reaching their third treatment cycle, n (% [95% CI])	113 (36.5 [31.1, 42.1])	179 (45.5 [40.5, 50.6])
Number of treatment cycles
Mean (SD)	2.6 (2.9)	3.2 (3.1)
Median (range)	2.0 (0.5–27.0)	2.0 (0.5–26.0)

*Each tablet contained regorafenib 40 mg; ^†Administration of < 84 tablets/28 days indicates that the patient initiated regorafenib at a lower than standard dose (80 or 120 mg/day, or a different combination)

CI, confidence interval; NCCN, National Comprehensive Cancer Network; SD, standard deviation